Guardant Health, Inc. Receives Consensus Rating of Moderate Buy from Analysts

Guardant Health, Inc. (NASDAQ:GH) Receives Consensus Rating of Moderate Buy from Analysts Guardant Health, Inc. (NASDAQ:GH – Get Free Report) has received an average rating of Moderate Buy from the twenty-two analysts that are covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and twenty have assigned a buy recommendation to the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $125.95. Insider Buying and Selling at Guardant Health In related news, CFO Michael Brian Bell sold 3,000 shares of Guardant Health stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $87.04, for a total value of $261,120.00. Following the sale, the chief financial officer owned 43,601 shares of the company’s stock, valued at approximately $3,795,031.04. The trade was a 6.44% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Medina Manuel Hidalgo sold 1,300 shares of the company’s stock in a transaction dated Friday, March 6th. The stock was sold at an average price of $91.54, for a total value of $119,002.00. Following the sale, the director owned 1,193 shares in the company, valued at $109,207.22. The trade was a 52.15% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 23,250 shares of company stock valued at $2,512,917. Corporate insiders own 6.10% of the company’s stock. Institutional Inflows and Outflows Several large investors have recently bought and sold shares of GH. V Square Quantitative Management LLC acquired a new position in shares of Guardant Health during the 4th quarter worth approximately $27,000. Chesapeake Asset Management LLC acquired a new stake in shares of Guardant Health in the 4th quarter valued at approximately $28,000. Thurston Springer Miller Herd & Titak Inc. bought a new position in shares of Guardant Health in the fourth quarter valued at $31,000. Elyxium Wealth LLC bought a new position in shares of Guardant Health in the fourth quarter valued at $35,000. Finally, Parallel Advisors LLC increased its holdings in Guardant Health by 164.7% during the fourth quarter. Parallel Advisors LLC now owns 352 shares of the company’s stock worth $36,000 after buying an additional 219 shares during the last quarter. 92.60% of the stock is owned by institutional investors and hedge funds. Guardant Health Stock Performance GH stock opened at $93.83 on Friday. The stock has a 50-day moving average price of $97.07 and a two-hundred day moving average price of $92.69. Guardant Health has a 1 year low of $36.36 and a 1 year high of $120.74. The stock has a market cap of $12.31 billion, a PE ratio of -28.35 and a beta of 1.64. Guardant Health last issued its quarterly earnings results on Thursday, February 19th. The company reported ($0.50) EPS for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.07). The firm had revenue of $281.27 million during the quarter, compared to the consensus estimate of $269.74 million. Guardant Health’s quarterly revenue was up 39.4% on a year-over-year basis. During the same quarter last year, the business posted ($0.62) EPS. On average, analysts forecast that Guardant Health will post -2.9 earnings per share for the current fiscal year. About Guardant Health Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide. The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.